Thalhammer-Scherrer Renate, Mitterbauer Gerlinde, Simonitsch Ingrid, Jaeger Ulrich, Lechner Klaus, Schneider Barbara, Fonatsch Christa, Schwarzinger Ilse
Department of Laboratory Medicine, University of Vienna, Austria.
Am J Clin Pathol. 2002 Mar;117(3):380-9. doi: 10.1309/C38D-D8J3-JU3E-V6EE.
Bone marrow cells of 325 adults with acute leukemia were immunophenotyped using a panel of monoclonal antibodies proposed by the European Group for the Immunological Characterization of Leukemias (EGIL). Of these, 97.2% could be assigned clearly to myeloid or lymphoid lineage (254 acute myeloid leukemias [AMLs], 48 B-cell lineage acute lymphoblastic leukemias [ALLs], 14 T-cell lineage ALLs), 1.8% as biphenotypic, and less than 1% as undifferentiated. Immunologic subtyping of ALLs revealed an association between early precursor phenotypes and coexpression of myeloid antigens, particularly CD15/CD65s coexpression and pre-pre-B cell-specific phenotypes and genotypes. The common ALL phenotype was associated with BCR-ABL translocation. Among AMLs, CD2 coexpression was almost exclusively restricted to French-American-British subtypes M3 variant and M4Eo and related molecular aberrations. The most valuable markers to differentiate between myeloperoxidase-negative AML subtypes M0 and ALLs were CD13, CD33, and CD117, typical of M0, and intracytoplasmic CD79a, intracytoplasmic CD3, CD10, and CD2, typical of B cell- or T cell-lineage ALL. Our results confirm excellent practicability of the EGIL proposalfor immunologic classification of acute leukemias. For myeloperoxidase-negative AMLs, we suggest a scoring system based on markers most valuable to distinguish between AML-M0 and ALLs.
采用白血病免疫特征欧洲小组(EGIL)推荐的一组单克隆抗体,对325例成年急性白血病患者的骨髓细胞进行免疫表型分析。其中,97.2%可明确归为髓系或淋系(254例急性髓系白血病[AML],48例B细胞系急性淋巴细胞白血病[ALL],14例T细胞系ALL),1.8%为双表型,不到1%为未分化型。ALL的免疫亚型分析显示,早期前体表型与髓系抗原共表达之间存在关联,尤其是CD15/CD65s共表达以及前前B细胞特异性表型和基因型。常见ALL表型与BCR-ABL易位有关。在AML中,CD2共表达几乎仅局限于法美英亚型M3变异型和M4Eo以及相关分子异常。区分髓过氧化物酶阴性AML亚型M0和ALL最有价值的标志物是M0典型的CD13、CD33和CD117,以及B细胞或T细胞系ALL典型的胞浆内CD79a、胞浆内CD3、CD10和CD2。我们的结果证实了EGIL提出的急性白血病免疫分类方案具有出色的实用性。对于髓过氧化物酶阴性AML,我们建议基于区分AML-M0和ALL最有价值的标志物建立一个评分系统。